Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06182579 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of RiMO-401 With Radiation in Advanced Tumors
A Phase 1 study, sponsored by Coordination Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT06182579 is a Phase 1 study that was terminated before completion, run by Coordination Pharmaceuticals. The registered enrollment target is 5 participants.
The verdict
NCT06182579, a Phase 1 study, was terminated before completion, sponsored by Coordination Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is a single arm study of RiMO-401 with radiation in patients with advanced tumors. A single escalation dose of RiMO-401 is intratumorally injected in a 3+3 study design to identify the recommended dose.
Interventions
- DRUG RiMO-401
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2024-02-22 |
| Est. Completion | 2025-06-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06182579
The ClinicalTrials.gov registry entry for NCT06182579 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Coordination Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RiMO-401 is the first listed.
NCT06182579 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06182579 about?
NCT06182579 is a clinical study titled "Phase I Study of RiMO-401 With Radiation in Advanced Tumors". This is a single arm study of RiMO-401 with radiation in patients with advanced tumors. A single escalation dose of RiMO-401 is intratumorally injected in a 3+3 study design to identify the recommended dose.
What is the current status of trial NCT06182579?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2024-02-22. Estimated completion is 2025-06-16.
What interventions are being tested in trial NCT06182579?
The interventions under investigation include: RiMO-401 (DRUG).
Who is sponsoring clinical trial NCT06182579?
This trial is sponsored by Coordination Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.